Intellia Therapeutics Inc. [NASDAQ: NTLA] loss -10.71% on the last trading session, reaching $71.09 price per share at the time. The company report on March 30, 2021 that Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis.
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the European Commission (EC) has granted orphan drug designation to NTLA-2001. This investigational medicinal product is being developed as a treatment for transthyretin amyloidosis (ATTR), a rare condition that can impact a number of organs and tissues within the body through the accumulation of misfolded transthyretin (TTR) protein deposits. NTLA-2001 is the first experimental CRISPR therapy – a Nobel Prize-winning technology – to be administered systemically via intravenous dosing to edit a gene, specifically the TTR gene, that encodes the production of TTR protein, inside the human body. In addition to being the first therapy of its kind, it also has the potential to be the first curative treatment and it may be able to halt and reverse ATTR progression.
“This news is a significant milestone for NTLA-2001 and the ATTR patient community,” said Intellia President and Chief Executive Officer John Leonard, M.D. “We are pleased that the EC recognizes the potential significant benefit of NTLA-2001 in the treatment of patients with this debilitating disease where there is no cure. We look forward to advancing the global development of this genome editing product in collaboration with Regeneron.”.
Intellia Therapeutics Inc. represents 61.29 million in outstanding shares, while the company has a total market value of $4.83 billion with the latest information. NTLA stock price has been found in the range of $70.71 to $79.06.
If compared to the average trading volume of 1.70M shares, NTLA reached a trading volume of 1104703 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Intellia Therapeutics Inc. [NTLA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NTLA shares is $78.46 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NTLA stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for Intellia Therapeutics Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on March 04, 2021. The new note on the price target was released on December 22, 2020, representing the official price target for Intellia Therapeutics Inc. stock. Previously, the target price had yet another raise to $40, while Truist analysts kept a Buy rating on NTLA stock.
The Average True Range (ATR) for Intellia Therapeutics Inc. is set at 7.07, with the Price to Sales ratio for NTLA stock in the period of the last 12 months amounting to 83.21. The Price to Book ratio for the last quarter was 8.27, with the Price to Cash per share for the same quarter was set at 8.80.
Trading performance analysis for NTLA stock
Intellia Therapeutics Inc. [NTLA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.59. With this latest performance, NTLA shares gained by 52.59% in over the last four-week period, additionally plugging by 242.27% over the last 6 months – not to mention a rise of 459.32% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NTLA stock in for the last two-week period is set at 52.85, with the RSI for the last a single of trading hit 50.95, and the three-weeks RSI is set at 53.14 for Intellia Therapeutics Inc. [NTLA]. The present Moving Average for the last 50 days of trading for this stock 65.87, while it was recorded at 78.25 for the last single week of trading, and 41.07 for the last 200 days.
Intellia Therapeutics Inc. [NTLA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Intellia Therapeutics Inc. [NTLA] shares currently have an operating margin of -235.51. Intellia Therapeutics Inc.’s Net Margin is presently recorded at -231.46.
Return on Total Capital for NTLA is now -31.96, given the latest momentum, and Return on Invested Capital for the company is -31.84. Return on Equity for this stock declined to -33.69, with Return on Assets sitting at -26.56. When it comes to the capital structure of this company, Intellia Therapeutics Inc. [NTLA] has a Total Debt to Total Equity ratio set at 7.46. Additionally, NTLA Total Debt to Total Capital is recorded at 6.94, with Total Debt to Total Assets ending up at 5.81. Long-Term Debt to Equity for the company is recorded at 6.38, with the Long-Term Debt to Total Capital now at 5.93.
Reflecting on the efficiency of the workforce at the company, Intellia Therapeutics Inc. [NTLA] managed to generate an average of -$430,228 per employee. Receivables Turnover for the company is 17.18 with a Total Asset Turnover recorded at a value of 0.11.Intellia Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.60 and a Current Ratio set at 9.60.
Intellia Therapeutics Inc. [NTLA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Intellia Therapeutics Inc. posted -0.63/share EPS, while the average EPS was predicted by analysts to be reported at -0.42/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -50.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NTLA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Intellia Therapeutics Inc. go to 30.00%.
An analysis of insider ownership at Intellia Therapeutics Inc. [NTLA]
There are presently around $4,398 million, or 82.60% of NTLA stock, in the hands of institutional investors. The top three institutional holders of NTLA stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 11,191,670, which is approximately -1.868% of the company’s market cap and around 1.20% of the total institutional ownership; VANGUARD GROUP INC, holding 5,131,197 shares of the stock with an approximate value of $364.78 million in NTLA stocks shares; and NIKKO ASSET MANAGEMENT AMERICAS, INC., currently with $362.87 million in NTLA stock with ownership of nearly -15.805% of the company’s market capitalization.
Positions in Intellia Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 160 institutional holders increased their position in Intellia Therapeutics Inc. [NASDAQ:NTLA] by around 10,522,520 shares. Additionally, 64 investors decreased positions by around 5,124,515 shares, while 27 investors held positions by with 46,221,752 shares. The mentioned changes placed institutional holdings at 61,868,787 shares, according to the latest SEC report filing. NTLA stock had 93 new institutional investments in for a total of 5,090,765 shares, while 15 institutional investors sold positions of 97,822 shares during the same period.